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Abstract
Background: Thyroid carcinoma is the most common endocrine malignancy and a common
cancer among the malignancies of head and neck. Noninvasive and convenient biomarkers for
diagnosis of papillary thyroid carcinoma (PTC) as early as possible remain an urgent need. The aim
of this study was to discover and identify potential protein biomarkers for PTC specifically.
Methods: Two hundred and twenty four (224) serum samples with 108 PTC and 116 controls
were randomly divided into a training set and a blind testing set. Serum proteomic profiles were
analyzed using SELDI-TOF-MS. Candidate biomarkers were purified by HPLC, identified by LC-MS/
MS and validated using ProteinChip immunoassays.
Results: A total of 3 peaks (m/z with 9190, 6631 and 8697 Da) were screened out by support
vector machine (SVM) to construct the classification model with high discriminatory power in the
training set. The sensitivity and specificity of the model were 95.15% and 93.97% respectively in the
blind testing set. The candidate biomarker with m/z of 9190 Da was found to be up-regulated in
PTC patients, and was identified as haptoglobin alpha-1 chain. Another two candidate biomarkers
(6631, 8697 Da) were found down-regulated in PTC and identified as apolipoprotein C-I and
apolipoprotein C-III, respectively. In addition, the level of haptoglobin alpha-1 chain (9190 Da)
progressively increased with the clinical stage I, II, III and IV, and the expression of apolipoprotein
C-I and apolipoprotein C-III (6631, 8697 Da) gradually decreased in higher stages.
Conclusion: We have identified a set of biomarkers that could discriminate PTC from non-cancer
controls. An efficient strategy, including SELDI-TOF-MS analysis, HPLC purification, MALDI-TOF-
MS trace and LC-MS/MS identification, has been proved successful.
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Background
Thyroid carcinoma is the most common endocrine malig-
nancy and a common cancer among the malignancies of
head and neck. It comprises 91.5% of all endocrine malig-
nancies and 1% of all malignant diseases [1]. An esti-
mated 33550 new cases are diagnosed annually in the
United States and recent statistics shows the incidence of
thyroid carcinoma has increased, especially in papillary
thyroid carcinomas (PTC) [2]. PTC is the most common
type, which accounts for 80% of all thyroid cancers [3].
Early accurate diagnosis and timely treatment are critical
for improving long-term survival of PTC patients. Many
diagnostic tools have been used for thyroid carcinoma,
such as sonography, computed tomography, magnetic
resonance imaging, cytological examination and fine-nee-
dle aspiration. Currently, although ultrasound-guided
fine-needle aspiration biopsy is considered as the most
effective test for distinguishing malignant from benign
thyroid nodules, its sensitivity is approximately 93% and
its specificity is 75% [4]. At the same time, researchers
have been seeking valuable biomarkers for thyroid carci-
noma diagnosis, such as galectin-3, fibronectin-1, CITED-
1, HBME1, cytokeratin-19 and TPO, and so on. What is
disappointing is that all these biomarkers either are lack-
ing specificity to some degree, or have a poor positive pre-
dictive value [5-9]. To distinguish a malignant thyroid
nodule from a benign lesion more accurately, the diag-
nostic test, however, still needs to be improved. Moreover,
a noninvasive screening method for thyroid malignancy
remains unavailable.
Recent advances in the proteomics study have introduced
novel techniques for the screening of cancer biomarkers
and improved early and accurate diagnosis of cancer dis-
eases to a new horizon [10]. Surfaced enhanced laser des-
orption/ionization time of flight mass spectroscopy
(SELDI-TOF-MS), which generates the protein fingerprint
by MS, has been proved a powerful tool for potential
biomarker discovery [11,12]. Recently, the SELDI-TOF-
MS analysis has been successfully used to identify specific
biomarkers for various cancers, such as ovarian cancer,
prostate cancer, pancreatic cancer, colon cancer, breast
cancer, etc [13-17]. In search of biomarkers for diagnosing
PTC, a few pilot studies based on proteomics were con-
ducted, in which SELDI-TOF-MS has been utilized
[18,19]. However, no specific protein biomarkers have
been identified and validated in those reports.
In this study, firstly, we used SELDI-TOF-MS technology
to screen potential protein patterns specific for PTC and
then purified the candidate protein biomarker peaks by
HPLC, identified by LC-MS/MS and finally confirmed
these biomarkers by ProteinChip Immunoassays. To the
best of our knowledge, this is the first time that proteins
biomarkers have been identified for PTC.
Results
Serum protein profiles and data processing
Serum samples from the training set were analyzed and
compared by SELDI-TOF-MS with WCX2 chip. All MS
data were baseline subtracted and normalized using total
ion current, and the peak clusters were generated by
Biomarker Wizard software. After carrying out Wilcoxon
rank sum tests to determine relative signal strength, 26
peaks with p value < 0.01 were obtained. Seven protein
peaks were found up-regulated and 19 peaks were found
down-regulated in PTC group (data not shown). From the
random combination of protein peaks with remarkable
variation, support vector machine (SVM) screened out the
combined model with maximum Youden index of the
predicted value, identifying 3 markers positioned at 9190,
6631 and 8697 respectively. In the PTC group, the 9190
Da protein was remarkably elevated while 6631 & 8697
Da proteins were significantly decreased (figure 1). The
descriptive statistics of these 3 markers are shown in Table
1. In addition, the level of 9190 Da protein progressively
increased with the clinical stage I, II, III and IV, and the
expression of 6631, 8697 Da proteins gradually decreased
in higher stages (figure 2). Combining 3 potential mark-
ers, using the method of leave-1-out for cross detection,
the sensitivity of discriminating 60 PTC and 40 normal
subjects was 98%, and its specificity was 97%.
Protein peak validation
The remaining 48 PTC and 76 control serum samples (20
healthy controls and 56 patients with benign thyroid
node) as a blind testing set, were analyzed to validate the
accuracy and validity of the classification model derived
from the training set. The descriptive statistics of the three
markers in 48 PTC patients and 76 non-cancer controls
are shown in Table 2. The classification model distin-
guished the PTC samples from controls with a sensitivity
of 95.15%, specificity of 93.97%, and positive predictive
value of 96.0%, respectively. The area under the receiver
operating characteristics (ROC) curve of this model was
0.971.
Purification and identification of candidate protein 
biomarkers
Serum samples from PTC patients were used for the puri-
fication of the up-regulated candidate protein biomarker
(9190 Da), and serum samples from healthy controls
Table 1: The relative peak intensity of three distinct protein 
spectra found in sera of PTC patients.
m/z Patients with PTC
(mean ± SD)
Healthy Individuals
(mean ± SD)
p
9190 6853.82 ± 1585.23 282.46 ± 118. 09 0.000538
6631 2706.56 ± 578.17 4697.16 ± 989.85 0.001381
8697 3017.98 ± 600.28 4924.32 ± 1048.11 0.001672Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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A representative mapping of SELDI-TOF-MS analysis of sera from PTC patients and healthy controls Figure 1
A representative mapping of SELDI-TOF-MS analysis of sera from PTC patients and healthy controls. Differen-
tially expressed proteins with potential diagnostic significance are arrowed. Top-group denotes sera from patients with PTC, in 
which the protein with m/z of 9190 Da was over-expressed. Bottom-group denotes sera from healthy individuals, in which the 
proteins with m/z of 6631 and 8697 Da were up-regulated.Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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A representative mapping of SELDI-TOF-MS analysis from different stages of PTC patients and non-cancer controls Figure 2
A representative mapping of SELDI-TOF-MS analysis from different stages of PTC patients and non-cancer 
controls. The level of the 9190 Da protein progressively increased with the clinical stage I, II, III and IV, and the expression of 
6631 and 8697 Da proteins gradually decreased in higher stages.Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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were used for the purification of the two down-regulate
proteins (6631, 8697 Da) using WCX SPE and C18 HPLC.
Figure 3 shows the results of MALDI-TOF-MS analysis of
the three purified candidate protein biomarkers.
After digestion with modified trypsin, the peptide mixture
was analyzed by nano-LC-MS/MS. Figure 4 shows the
results of the LC-MS/MS chromatogram (A) and MS/MS
spectrum of one identified peptide (B) from protein
(8697 Da). Table 3 shows the results of identification of
the three candidate protein biomarkers. They were hap-
toglobin alpha-1 chain (9190 Da) [NCBI:P00738], apoli-
poprotein C-I (6631 Da) [NCBI:P02654] and
apolipoprotein C-III (8697 Da) [NCBI:CAA25233]. The
whole sequence of the three candidate protein markers is
given by combination of high sequence coverage and
accurate molecular weight (MW) measurement using
MALDI-TOF-MS.
Validation of three candidate protein biomarkers
A ProteinChip-array-based immunoassay (Ciphergen Bio-
systems) was used to specifically capture haptoglobin
alpha-1 chain, apolipoprotein C-I and apolipoprotein C-
III from crude serum samples and to confirm the signifi-
cance of each marker. The anti-haptoglobin alpha-chain
antibody specifically captured the previously identified
9190 Da protein. The anti-apolipoprotein C-I array was
developed to capture apolipoprotein C-I (6631 Da) and
the apolipoprotein C-III antibody against specifically cap-
tured apolipoprotein C-III (8697 Da). (Figure 5)
Discussions
In this study, we obtained serum protein mass spectra
from PTC patients and controls using SELDI-TOF-MS.
Based on the serum proteomic profiles, we constructed a
classification model to discriminate PTC patients from
non-cancer controls. One of the challenges in the analysis
of SELDI-TOF-MS-generated data is to reduce the false
protein peaks, in which the discriminatory power is due to
random variation [20]. To solve this problem in the data
processing of this experiment, we eliminated noise by dis-
crete wavelength, identified mass-charge peaks of speci-
mens using the method of local extremum, and clustered
mass-charge peaks by setting 10% as the minimum
threshold. Wilcoxon rank sum test analysis assessed the
relative importance of each peak in the discrimination of
2 kinds of specimen according to P values. Furthermore,
SVM was employed in our experiment, which is a kind of
classification technology proposed by Vapnik and others.
In the model discrimination, the popularization, model
selection, overfitting, latitude disaster, and other prob-
lems of the small specimen model have been solved suc-
cessfully in SVM [21-23]. The procedures included
randomly combining the remarkably different mass-
charge peaks and inputting them into SVM, screening out
the markers, building the discrimination model, and then
using the method of leave one out to assess the model by
means of cross verification. By combination among these
procedures mentioned above, the popularization of the
model building and the accuracy of the prediction were
ensured. The classification model could discriminate
patients with PTC from non-cancer controls with a sensi-
tivity of 95.15% and a specificity of 93.97% in the blind
testing set. The up-regulated candidate protein biomarker
was identified as haptoglobin alpha-1 chain (9190 Da).
Another two down-regulated candidate protein biomark-
ers (6631 and 8697 Da) were identified as apolipoprotein
C-I and apolipoprotein C-III.
Among the proteins identified by LC-MS/MS, hap-
toglobin alpha-1 chain was significantly elevated in PTC
patients and this protein may play a critical role in the
development of PTC. Intact haptoglobin, composed of
two different polypeptides (alpha and beta-chains), is an
acute phase protein capable of binding haemoglobin and
preventing iron loss [24]. It was reported that body iron
could promote neoplastic cell growth and accumulate in
cancer cells more than in normal cells [25]. Furthermore,
a few other studies have demonstrated that there is a
higher cancer risk in patients with larger iron stores than
those with small iron stores [26]. Collectively, highly
expressed haptoglobin results in a high hemoglobin/iron
existence and raises the possibility of a causative involve-
ment of iron-derived oxidative stress in the tumour devel-
opment. Recently, there are several reports in the literature
showing increased expression of haptoglobin in ovarian
cancer, prostatic carcinoma and pancreatic cancer [27-29],
and the level of haptoglobin alpha chain up-regulated in
serum of breast cancer [30]. However, it is necessary to
understand more clearly of the role of haptoglobin alpha-
1 chain in the development of PTC through further stud-
ies of biological mechanisms of thyroid carcinoma.
Apolipoproteins (APOs) are lipid carriers and previous
studies about APO mainly focused on lipoprotein metab-
olism. Recently, APOs have been reported to regulate
many cellular function. For example, the protein kinase
Akt can be elicited by APO C-I, which in turn promotes
growth factor-mediated cell survival and block apoptosis
[31]. In this study, the APO C-I is down-regulated in the
serum of PTC patients, which indicates that APO C-I may
be related to PTC. Thus, besides the function of APO C-I
in lipid metabolism, additional function of APO C-I in
Table 2: The descriptive statistics of these 3 markers in the blind 
testing set.
m/z Patients with PTC
(mean ± SD)
Non-cancer Controls
(mean ± SD)
p
9190 6798.89 ± 1517.76 271.35 ± 102.04 0.000526
6631 2786.03 ± 596.11 4705.23 ± 991.45 0.001402
8697 3011.62 ± 598.13 4912.36 ± 1042.79 0.001669Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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cancerogenesis may also exist. However, the mechanism
of how APO C-I is degraded in PTC is not very clear, and
further research is required. APO C-III is primarily synthe-
sized in the liver and in a minor degree in the small intes-
tine. The regulatory elements that control both hepatic
and intestinal transcription of the human APO C-III gene
are localized between nucleotides -792 and -25 of the
APO C-III promoter. The mechanism of why APO C-III
was decreased in PTC may be as follows. Orphan mem-
bers of the nuclear hormone receptor superfamily can
bind to the hormone response elements (HREs), and
strongly enhance or repress APO C-III promoter's activity.
It was reported that a combination of RXRalpha and
T3Rbeta could repress the APO C-III promoter's activity in
the presence of T3 [32]. In addition, the thyroid stimulat-
ing hormone (TSH) level was significantly higher in PTC
than in non-cancer control [33], correspondingly, T3
increased, thus the expression of APO C-III was possibly
inhibited in PTC patients.
Conclusion
In summary, we have identified a set of protein peaks that
could discriminate PTC from non-cancer controls. From
the protein peaks specific for PTC disease, we identified
haptoglobin alpha-1 chain, apolipoprotein C-I and apol-
ipoprotein C-III as potential proteomic biomarkers of
PTC. Further studies with larger sample sizes will be
needed to verify the specific protein markers. An efficient
strategy, composed of SELDI-TOF-MS analysis, HPLC
purification, MALDI-TOF-MS trace and LC-MS/MS identi-
fication has been proved very successful.
Materials and methods
Patients and serum samples
Serum samples were obtained from 224 individuals with
informed consent in the Department of General Surgery,
the First Affiliated Hospital of Zhengzhou University.
These 224 individuals included 108 patients with PTC, 56
patients with benign thyroid node, and 60 healthy indi-
viduals. Patients with PTC had a median age of 43 years
(ranging from 23 to 75 years, 27 men and 81 women),
and the sera was obtained at the time of diagnosis. All 108
patients were distributed in 4 stages according to UICC. In
stage I there were 85 patients, stage II, III & IV consisted of
12, 8 & 3 patients respectively. The diagnosis, stage and
other information about these patients are listed in Table
4 and Table 5. Inclusion criteria for the study were
patients with a confirmed diagnosis of PTC, the ability to
provide written, informed consent, and without any pre-
vious treatment. Patients with benign thyroid node and
healthy donors were defined as controls in this study. The
benign thyroid node group and the healthy individual
group were age- and gender-matched with the PTC group.
Pathological diagnosis of all the PTC and benign thyroid
nodes were confirmed independently by two patholo-
gists. All serum samples were collected preoperatively in
the morning before breakfast. The sera were left at room
temperature for 1 h, centrifuged at 3000 rpm for 10 min,
and then stored at -80°C.
Reagents and instruments
Sinapinic acid (SA) was purchased from Fluka (USA). Pro-
teinChip Biosystems (Ciphergen PBS II plus SELDI-
TOFMS) and WCX2 chip were purchased from Ciphergen
Biosystems (USA). All other SELDI-TOF-MS related rea-
gents were acquired from Sigma (USA). Ziptip C18 was
purchased from Millipore (USA). Trypsase was purchased
from Promega (USA). IAM was purchased from Appli-
Chem (GER). DTT was purchased from BIO-RAD (GER).
MALDI-TOF-MS was purchased from Kratos Analytical Co
(UK) and HPLC was purchased from Shimadzu (JPN).
LC-MS/MS was purchased from Thermo Electron Corpo-
ration (USA).
SELDI-TOF-MS analysis of serum protein profiles
Protein profiling of serum samples was determined by
SELDI-TOF-MS using the WCX2 (weak cation exchange)
Proteinchip arrays (Ciphergen Biosystems, USA). Frozen
serum samples were defrosted on ice and spun at 10 000
MALDI-TOF-MS spectra of three purified potential protein  markers Figure 3
MALDI-TOF-MS spectra of three purified potential 
protein markers.Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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rpm for 5 min at 4°C. Each serum sample (10 μl) was
denatured by addition of 20 μl of U9 buffer (9 M urea, 2%
CHAPS, 50 mM Tris-HCI, 1% DTT, PH 9.0) and vortexed
at 4°C for 30 min. Each sample was then diluted in 108
μl of low stringency buffer (0.1 M sodium acetate, PH 4.0)
and 100 μl of each diluted serum sample was hybridized
with WCX2 proteinchip arrays, which was held by a bio-
processor (Ciphergen Biosystems) and preactivated twice
with 150 μl low stringency buffer at room temperature for
5 min. The diluted serum sample was added on the sur-
face of the WCX2 chip for 60 min at room temperature.
Each spot was then washed three times with appropriate
buffers of various PHs and ionic strengths to eliminate
non-adsorbed proteins. After drying the array surface in
the air, 1 μl saturated sinapinic acid (SA) matrix in 50%
ACN and 0.5% TFA was applied and allowed to dry. MS
analysis was performed on a PBS-II ProteinChip reader
(Ciphergen Biosystems). Mass peak detection was ana-
lyzed using ProteinChip Biomarker Software version 3.1
(Ciphergen Biosystems). The mass spectra of the proteins
were generated using an average of 140 laser shots at a
laser intensity of 170 arbitrary units and detector sensitiv-
ity was set at 6. For data acquisition of low-molecular-
weight proteins, the optimize detection mass range was
set from 2 to 20 kDa for all study sample profiles. The
instrument was calibrated by the All-in-one peptide
molecular mass standard (Ciphergen Biosystems).
Bioinformatics and biostatistics
Patients with PTC were split into a training set and a blind
testing set. Sixty samples of PTC patients (45 stage I, 8
stage II, 4 stage III, 3 stage IV) and 40 healthy controls
were selected for a training sample set randomly. To eval-
uate the accuracy and validity of the classification model,
the remaining 48 samples of PTC patients (40 stage I, 4
stage II, 4 stage III) and 76 controls (20 healthy controls
and 56 patients with benign thyroid node) were selected
for a blind testing set. (Table 6).
The first step of data analysis was to use the undecimated
discrete wavelet transform (UDWT) method to denoise
the signals. Secondly, the spectra were subjected to base-
line correction by aliging with a monotone local mini-
mum curve and mass calibration. The proteomic peaks
were detected and quantified by an algorithm that takes
the maximal height of every denoised, baseline-corrected,
and calibrated mass spectrum into account. Thirdly, the
peaks were filtered to maintain a S/N of more than three.
The S/N of a peak is the ratio of the height of the peak
above the baseline to the wavelet-defined noise. Finally,
to match peaks across spectra, we pooled the detected
peaks if the relative difference in their mass sizes was not
more than 0.3%. The minimal percentage of each peak,
appearing in all the spectra, is specified to ten. The
matched peak across spectra is defined as a peak cluster. If
a spectrum does not have a peak within a given cluster, the
Table 3: Identification of the three potential protein biomarkers with identified peptides and covered sequence.
m/z Protein Name Peptides Identified Sequence*
9190 Haptoglobin α-chain K.LRTEGDGVYTLNNEK.Q addgcpkppeiahgyvehsvryqck nyyklrtegdgvytlnnekqwinka 
vgdklpeceavcgkpknpanpvq
R.YQCKNYYK.L
K.AVGDKLPECEAVCGK.P
K.QWINKAVGDK.L
R.TEGDGVYTLNNEK.Q
K.LPECEAYCGKPK.N
K.PKNPANPVQ.-
6631 Apolipoprotein C-I G.TPDVSSALDK.L tpdvssaldklkefgntledkarelis rikqselsakmrewfsetfqkvkeklkids
K.EFGNTLEDKAR.E
K.LKEFGNTLEDK.A
R.EWFSETFQK.V
G. TPDVSSALDKLK.A
K.MREWFSETFQK.V
K.ARELISRIK.Q
8697 Apolipoprotein C-III K.DALSSVQESQVAQQAR.G seaedasllsfmqgymkhatktakdalssvq esqvaqqargwvtdgfsslkdywstvkd 
kfsefwdldpevrptsavaa
R.GWVTDGFSSLK.D
K.TAKDALSSVQESQVAQQAR.G
R.GWVTDGFSSLKDYWSTVK.D
K.DKFSEFWDLDPEVR.P
K.DKFSEFWDLDPEVRPTSAVAA.-
*: Bold letters show the covered sequence by identified peptideMolecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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Results of the identification of protein (8697 Da) by LC-MS/MS Figure 4
Results of the identification of protein (8697 Da) by LC-MS/MS. (A) Chromatogram of peptide mixture. (B) MS/MS 
spectrum of one peptide.Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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Representative spectra from ProteinChip array with specific immobilized antibodies Figure 5
Representative spectra from ProteinChip array with specific immobilized antibodies. (A) Representative spectra 
of the negative control (nonspecific rabbit IgG). (B) Representative spectra from ProteinChip array with anti-haptoglobin alpha 
chain antibody. (C) Representative spectra from ProteinChip array with anti-apolipoprotein C-I. (D) Representative spectra 
from ProteinChip array with anti-apolipoprotein C-III.Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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Table 4: The diagnosis, staging and other information about PTC patients in the training set.
Patient ID Age (years) Sex 
(F = female 
M = male)
Diagnosis Stage Tumor size (cm) Cervial lymph 
node metastasis
Distant 
metastases
Patients<45 years
P38 23.01 F PTC I 0.5 None NO
P78 29.98 F PTC I 1.0 None NO
P65 32.12 F PTC I 1.0 None NO
P81 36.45 F PTC I 0.8 None NO
P36 38.50 F PTC I 0.5 None NO
P43 39.56 F PTC I 1.0 None NO
P16 40.05 F PTC I 0.8 None NO
P44 40.11 M PTC I 1.0 Yes(VI lymph node) NO
P37 40.25 F PTC I 1.6 None NO
P5 40.36 F PTC I 1.0 None NO
P18 40.50 M PTC I 0.6 None NO
P80 40.81 M PTC I 0.7 None NO
P93 40.90 F PTC I 1.0 None NO
P67 41.00 F PTC I 1.0 None NO
P46 41.08 F PTC I 1.5 None NO
P9 41.10 M PTC I 1.8 Yes(VI lymph node) NO
P35 41.26 M PTC I 1.0 None NO
P47 41.38 F PTC I 0.8 None NO
P13 41.44 F PTC I 1.0 None NO
P6 41.52 M PTC I 0.6 None NO
P17 41.55 F PTC I 1.5 Yes(VI lymph node) NO
P40 41.62 F PTC I 0.8 None NO
P64 41.71 F PTC I 0.8 None NO
P111 41.89 M PTC I 1.3 None NO
P69 42.14 M PTC I 1.2 None NO
P2 42.25 F PTC I 1.6 Yes(VI lymph node) NO
P12 42.36 F PTC I 0.8 None NO
P7 42.56 F PTC I 0.8 None NO
P4 42.73 M PTC I 0.6 None NO
P49 43.20 F PTC I 1.2 None NO
P8 43.66 M PTC I 1.5 Yes(VI lymph node) NO
P70 43.80 F PTC I 0.7 None NO
P42 44.10 F PTC I 1.5 None NO
P114 44.30 M PTC I 0.8 None NO
P83 44.45 F PTC I 1.3 None NO
P99 44.60 M PTC I 0.6 None NO
Patients>45 years
P105 45.05 F PTC I 0.8 None NO
P71 45.58 M PTC II 2.5 None NO
P107 45.75 M PTC I 0.7 None NO
P60 45.81 F PTC II 2.5 None NO
P10 46.48 F PTC I 0.8 None NO
P104 46.40 F PTC II 2.3 None NO
P14 46.90 F PTC II 2.5 None NO
P52 47.10 F PTC I 0.7 None NO
P11 47.64 M PTC III 3.5 Yes(VI lymph node) NO
P88 47.89 F PTC I 0.6 None NO
P22 48.50 F PTC I 0.8 None NO
P73 48.81 M PTC I 0.7 None NO
P87 49.56 F PTC III 4.5 Yes(VI lymph node) NO
P100 49.89 F PTC II 2.8 None NO
P25 50.25 F PTC III 3.8 Yes(VI lymph node) NO
P85 50.89 F PTC I 0.7 None NO
P101 57.14 M PTC II 2.5 None NO
P32 58.21 F PTC II 2.3 None NO
P103 60.10 F PTC I 0.8 None NO
P53 61.12 F PTC II 2.5 None NOMolecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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maximal height within the cluster will be assigned to its
peak value. The normalization was performed only with
the identified peak clusters.
To distinguish between data of different groups, we used
a nonlinear SVM classifier, originally developed by
Vladimir Vapnik, with a radial-based function kernel, a
parameter Gamma of 0.6, and a cost of the constrain vio-
lation of 19. The leave-one-out crossing validation
approach was applied to estimate the accuracy of this clas-
sifier. The capability of each peak in distinguishing data of
different groups was estimated by the p value of Wilcox-
son T-test. The p value was set at 0.01 to be statistically sig-
nificant. The remaining 48 samples of PTC patients and
76 controls (20 healthy controls and 56 patients with
benign thyroid node), were analyzed to test the classifica-
tion model. PTC and control samples were then discrimi-
nated based on their proteomic profile characteristics. The
sensitivity was defined as the probability of predicting
PTC cases, the specificity was defined as the probability of
predicting control samples. The positive predictive value
was defined as the probability of PTC if a test result was
positive.
Serum fractionation
Serum samples both from healthy controls and PTC
patients were selected for the purification of the three can-
didate protein biomarkers. The serum sample was mixed
with U9 buffer (1:2, v/v) and incubated for 30 min at
room temperature. The sample was then diluted in 5 mL
WCX binding buffer (50 mM NaAc, pH 4.0) and loaded
to the CM Ceramic Hyper D WCX SPE column (6 × 10
mm, Pall Life science, USA). After washing with 2 mL of
WCX binding buffer, the column was eluted with 5 ml of
eluting buffer (2 M NaCl, 50 mM NaAc, pH 4.0) at a flow
rate of 0.5 ml/min. The eluted fraction was further puri-
fied using HPLC.
Purification of candidate protein markers using HPLC
HPLC separation was performed using SCL-10AVP (Shi-
madzu, Japan) with a Sunchrom C18 column (250 × 4.6
mm, 5 μm particle size, 300 Å) (The Great Eur-Asia Sci-
Tech Development Co. Ltd, Beijing, China) and a C18
guard column (10 × 3 mm, Shimadzu, Japan). The mobile
phase consisted of solvent A (5% ACN, 0.1% TFA) and
solvent B (90% ACN, 0.1% TFA). The HPLC separation
was achieved with a linear solvent gradient: 100% A (0
min)-15% B (15 min)-65% B (65 min)-100% B (100
min) at a flow-rate of 0.5 ml/min. The eluate was detected
at multiple wavelengths of 214, 254, 280 nm. Each peak
fraction was collected and concentrated using SpeedVac,
and then analyzed using AXIMA-CFRTM plus MALDI-TOF
mass spectrometer (Shimadzu/Kratos, Manchester, UK) in
linear mode to trace the candidate protein biomarkers
with α-cyano-4-hydrorycinnamic acid (CHCA) as matrix.
Identification of candidate protein biomarkers by LC-MS/
MS
In-solution digestion of each concentrated fraction, which
contains one candidate protein biomarker, was per-
formed with a standard protocol. Briefly, each fraction
was dissolved in 25 mM NH4HCO3, and reduced with 10
mM DTT for 1 hour, alkylated by 40 mM iodoacetamide
in the dark for 45 min at room temperature, and then 40
mM DTT was added to quench the iodoacetamide for 30
min at room temperature. Then proteins were proteolysed
with 20 ng of modified trypsin (Promega, Madison, WI)
in 25 mM NH4HCO3 overnight at 37°C. The supernatant
was collected and peptides were further extracted in 0.1%
acetic acid and 60% acetonitrile. Peptide extracts were vac-
uumdried and resuspended in 20 μl of water for mass
analysis. Protein digests obtained above were loaded onto
a home-made C18 column (100 mm × 100 μm) packed
with Sunchron packing material (SP-120-3-ODS-A, 3 μm)
and followed with nano-LC-ESI-MS/MS analysis. The LTQ
mass spectrometer was operated in a data-dependent
mode, in which the initial MS scan recorded the m/z ratios
of ions over the mass range from 400-2000 Da firstly, and
then the five most abundant ions were automatically
selected for subsequent collision-activated dissociation.
All MS/MS data were searched against a human protein
database downloaded from NCBI using the SEQUEST
program (Thermo, USA).
Confirmation of candidate protein biomarkers using 
ProteinChip Immunoassays
To confirm the identity of the candidate protein biomark-
ers, all samples from the initial experiments were reana-
lyzed by using ProteinChip immunoassays (Ciphergen
Biosystems). Specific antibody arrays were prepared by
P23 65.84 F PTC IV 4.0 Yes(hibateral) Yes
(pulmonary 
metastasis)
P54 68.19 F PTC IV 3.5 Yes(mediastinal) Yes
(osseous metastasis)
P24 72.31 F PTC III 3.6 None NO
P63 74.98 F PTC IV 3.5 Yes(hibateral) Yes
(pulmonary 
metastasis)
Table 4: The diagnosis, staging and other information about PTC patients in the training set. (Continued)Molecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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covalently coupling the appropriate antibodies to preacti-
vated ProteinChip arrays (Ciphergen Biosystems). Anti-
bodies (anti-human haptoglobin alpha-chain, ms1750rb-
h; anti-human apolipoprotein C-I, ab9106; anti-human
apolipoprotein C-III, mab002-74/3) were covalently cou-
pled to PS20 arrays, respectively. After blocking with BSA
and washing to remove uncoupled antibodies, antibody-
coated spots were incubated with 1.5 μL of serum samples
and 3 μL of binding buffer (0.1 M Na3PO4, 0.5 M urea,
0.5% CHAPS, pH 7.2) for 90 min. Spots were then
Table 5: The diagnosis, staging and other information about PTC patients in the blind testing set.
Patient ID Age (years) Sex 
(F = female 
M = male)
Diagnosis Stage Tumor size (cm) Cervial lymph 
node metastasis
Distant 
metastases
Patients<45 years
P57 25.50 F PTC I 0.6 None NO
P64 41.71 F PTC I 0.8 None NO
P15 31.25 F PTC I 0.5 None NO
P19 34.16 F PTC I 0.6 None NO
P79 37.71 F PTC I 0.7 None NO
P91 38.63 F PTC I 1.2 Yes (VI lymph node) NO
P110 39.80 F PTC I 1.0 None NO
P34 40.20 F PTC I 0.6 None NO
P66 40.28 M PTC I 0.7 None NO
P92 40.42 F PTC I 1.0 None NO
P109 40.56 F PTC I 0.5 None NO
P1 40.85 F PTC I 0.7 None NO
P94 41.15 F PTC I 0.7 None NO
P108 41.30 F PTC I 1.6 Yes (VI lymph node) NO
P95 41.39 M PTC I 1.2 None NO
P68 41.46 F PTC I 0.8 None NO
P106 41.58 M PTC I 1.5 None NO
P96 41.66 F PTC I 0.7 None NO
P30 41.82 F PTC I 1.0 None NO
P39 42.05 F PTC I 1.0 None NO
P41 42.20 F PTC I 1.8 None NO
P89 42.31 M PTC I 0.7 None NO
P48 42.45 M PTC I 1.2 None NO
P98 42.68 F PTC I 1.5 None NO
P113 42.80 F PTC I 0.9 None NO
P97 43.40 F PTC I 1.0 None NO
P29 43.72 F PTC I 1.6 Yes (VI lymph node) NO
P90 44.26 M PTC I 0.8 None NO
P50 44.54 F PTC I 0.7 None NO
P56 44.98 F PTC I 0.7 None NO
Patients>45 years
P28 45.52 F PTC I 0.8 None NO
P27 45.66 F PTC II 2.8 None NO
P51 46.05 F PTC I 0.6 None NO
P55 46.62 M PTC I 0.8 None NO
P72 46.85 F PTC II 2.8 None NO
P84 47.25 F PTC I 0.6 None NO
P33 48.30 F PTC I 0.8 None NO
P102 48.73 F PTC III 3.8 Yes (VI lymph node) NO
P31 49.14 F PTC I 0.6 None NO
P20 49.60 F PTC I 0.9 None NO
P61 49.91 M PTC I 0.8 None NO
P77 50.40 F PTC I 0.8 None NO
P21 52.30 F PTC I 0.9 None NO
P74 54.56 M PTC III 3.5 Yes (VI lymph node) NO
P62 56.05 F PTC III 3.5 Yes (VI lymph node) NO
P86 62.13 M PTC II 2.8 None NO
P75 67.40 F PTC II 2.5 None NO
P76 68.56 F PTC III 3.8 None NOMolecular Cancer 2009, 8:79 http://www.molecular-cancer.com/content/8/1/79
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washed with PBST (0.5% Triton X-100), PBS and deion-
ized water twice respectively before drying. SELDI-TOF-
MS analysis was performed on a PBS-II ProteinChip
reader with CHCA as matrix.
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